HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 4, 2017, Halozyme Therapeutics, Inc. (the Company) held its
Annual Meeting of Stockholders. Of the 129,801,310 shares of the
Company’s common stock outstanding as of the record date,
108,223,921 shares were represented at the annual meeting.
The stockholders considered four proposals at the meeting, each of
which is described in more detail in the Company’s definitive
proxy statement filed with the Securities and Exchange Commission
on March 24, 2017. The number of votes cast for and against (or
withheld) and the number of abstentions and broker non-votes with
respect to each matter voted upon are set forth below.
Proposal 1: Election of two Class I directors to hold office for a
three-year term expiring at the 2020 Annual Meeting of Stockholders
or until their respective successors are duly elected and
qualified:
Names
Votes For
Withheld
Broker Non-Votes
Kenneth J. Kelley
80,820,900
1,924,694
25,478,327
Matthew L. Posard
80,896,995
1,848,599
25,478,327
Each of the foregoing candidates were elected and each received
affirmative votes from more than a majority of the outstanding
shares.
Proposal 2: The advisory vote on the compensation of the Company’s
named executive officers was as follows:
Votes For
Votes Against
Abstain
Broker Non-Votes
60,653,152
21,886,201
206,241
25,478,327
The foregoing proposal was approved.
Proposal 3:>The advisory vote on the frequency of holding future
advisory votes on the compensation of the Companys named executive
officers was as follows:
One Year
Two Years
Three Years
Abstain
81,283,530
150,103
894,589
417,372
Consistent with the Boards recommendation to approve holding an
annual advisory vote on executive compensation and in light of the
voting results set forth above, the Company will hold an annual
advisory vote on executive compensation until the next required
vote on the frequency of stockholder votes on the compensation of
executives.
Proposal 4:>The vote on a proposal to ratify the selection of
Ernst Young LLP as the Company’s independent registered public
accounting firm for the fiscal year ending December 31, 2017 was as
follows:
Votes For
Votes Against
Abstain
Broker Non-Votes
107,909,067
189,684
125,170
–
The foregoing proposal was approved.


About HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) Recent Trading Information

HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) closed its last trading session down -0.16 at 13.99 with 546,351 shares trading hands.